Modified chemo combo vs standard for late-relapsed lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different chemotherapy combinations for people with diffuse large B-cell lymphoma that has come back more than 12 months after initial treatment. The goal is to see which regimen works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma that returned more than 12 months after your last treatment.
- You are 18 years or older.
- You have at least one tumor that can be measured on a scan (lymph node larger than 1.5 cm or other lesion larger than 1 cm).
- Your overall health is good enough that you can perform daily activities (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within acceptable ranges as determined by standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests a new sequence of chemotherapy drugs for people with intermediate-to-high risk diffuse large B-cell lymphoma who did not achieve complete remission after their first two cycles of standard treatment. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.